Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.03 SGD | +1.98% | 0.00% | -5.56% |
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The firm trades with high earnings multiples: 25.82 times its 2024 earnings per share.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BSL Stock
- Ratings Raffles Medical Group Ltd